Plain-English translation of NCT06690775 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called for women with advanced ovarian cancer that has come back or stopped responding to platinum-based chemotherapy. The medication works by targeting a specific protein called claudin 6 found on some ovarian cancer cells. Researchers want to learn whether this treatment is safe and effective for this difficult-to-treat form of cancer.
Ovarian cancer that becomes resistant to platinum drugs is very hard to treat, and patients need new options. This medication targets a specific feature of some ovarian cancers that standard treatments may miss, offering hope for patients who have limited choices after their cancer stops responding to conventional chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication on day 1 of each 21-day cycle, with a supportive injection on day 4 to help protect your blood cells. The study involves multiple visits for blood tests, imaging scans to measure your cancer, and check-ins to monitor how you're tolerating the treatment. Your participation would continue for as long as the medication is helping your cancer and you are not experiencing unmanageable side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States